In a closely watched case, Bayer and Novartis lost a legal battle against the U.K.’s National Health Service for favoring a less-expensive drug for a serious eye condition that can save the agency millions of dollars.

At issue was the Avastin cancer treatment, which is widely used by many physicians to treat age-related wet macular degeneration, even though the Roche (RHHBY) drug is not approved for that use. The medicine, however, is generally much cheaper than two other drugs that are approved for wet AMD — Lucentis, which is sold in the U.K. by Novartis (NVS), and Eylea, which Bayer (BAYRY) markets in the country.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Let us savor the “eye”-rony of this conflict. Big pharma in the US had no trouble with the common knowledge that up to 50% of scrips were written for ‘off-label’ uses in the ’90s (at least). That situation increased sales. Now this off-label use is anathema because … of sales? Ah, the irony!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy